|
1
|
Rikova K, Guo A, Zeng Q, Possemato A, Yu
J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al: Global survey
of phosphotyrosine signaling identifies oncogenic kinases in lung
cancer. Cell. 131:1190–1203. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wiesner T, He J, Yelensky R, Esteve-Puig
R, Botton T, Yeh I, Lipson D, Otto G, Brennan K, Murali R, et al:
Kinase fusion are frequent in Splitz tumors and spitzoid melanomas.
Nat Commun. 5:31162014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shaw AT, Ou SHI, Bang YJ, Camidge DR,
Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa
DB, et al: Crizotinib in ROS1-rearranged non-small-cell lung
cancer. N Engl J Med. 371:1963–1971. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gendarme S, Bylicki O, Chouaid C and
Guisier F: ROS-1 fusions in non-small-cell lung cancer:
Evidence to date. Curr Oncol. 29:641–658. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu J, Lin Y, He X, Yang H, He P, Fu X, Li
G and Gu X: Comparison of detection methods and follow-up study on
the tyrosine kinase inhibitors therapy in non-small cell lung
cancer patients with ROS1 fusion rearrangement. BMC Cancer.
16:5992016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ke W, Xu Z and Xue L: ROS1 gene
rearrangement and clinicopathological characteristics in Chinese
NSCLC patients. Int J Clin Exp Pathol. 9:5594–5599. 2016.
|
|
7
|
Zhao J, Zheng J, Kong M and Zhou J, Ding W
and Zhou J: Advanced lung adenocarcinomas with ROS1-rearrangement
frequently show hepatoid cell. Oncotarget. 7:74162–74170. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shaw AT, Riety GJ, S, Bang YJ, Kim DW,
Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI,
Usari T, et al: Crizotinib in ROS1-rearranged advanced
non-small-cell lung cancer (NSCLC): Updated results, including
overall survival, from PROFILE 1001. Ann Oncol. 30:1121–1126. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Y, Zhang X, Zhang R, Xu Q, Yang H,
Lizaso A, Xu C, Liu J, Wang W, Ou SHI, et al: Clinical and
molecular factors that impact the efficacy of first-line crizotinib
in ROS1-rearranged non-small-cell lung cancer: A large multicenter
retrospective study. BMC Med. 19:2062021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Z, Shen L, Ding D, Huang J, Zhang J,
Chen Z and Lu S: Efficacy of crizotinib among different types of
ROS1 fusion partners in patients with ROS1-rearranged non-small
cell lung cancer. J Thorac Oncol. 13:987–995. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hicks JK, Boyle T, Albacker LA, Madison R,
Frampton G and Creelan BC: Clinical activity of crizotinib in lung
adenocarcinoma harboring a rare ZCCHC8-ROS1 fusion. J Thorac Oncol.
13:e148–e150. 2018. View Article : Google Scholar : PubMed/NCBI
|
